Active surrender.
eric.collisson@ucsf.edu
Eric A
EA
Collisson
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D002471:Cell Transformation, Neoplastic / Q000235:genetics / Q000473:pathology; D006801:Humans; D008495:Medical Oncology / Q000379:methods / Q000639:trends*; D008545:Melanoma / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D008954:Models, Biological; D058990:Molecular Targeted Therapy; D009154:Mutation / Q000502:physiology; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics / Q000502:physiology; D015398:Signal Transduction / Q000235:genetics; D012878:Skin Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D016896:Treatment Outcome; D048490:raf Kinases / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism / Q000502:physiology
D000970:Antineoplastic Agents; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D048490:raf Kinases